Pharmaceuticals Press Release

2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Date Title
19 August 2019 BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.
05 August 2019 Randomized double-blinded study to commence on DigiFab® for kidney injury related to CABG surgery
 
11 July 2019 NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®
29 April 2019 Trial finds patients receiving CroFab® antivenom less likely to use opioids for pain control
05 March 2019 New research validates clinical value of treating Copperhead envenomation with CroFab®
14 February 2019 A Retrospective Study of Medicare claim data shows patients treated with Voraxaze® had shorter hospitalizations and lower mortality
08 January 2019 BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
26 September 2018 BTG Announces Replacement Policy for Expired CroFab®
13 September 2018 FDA Approves CroFab® Product Improvements
16 November 2017 New consensus guidelines provide specific recommendations for use of Voraxaze® in patients with dela
13 September 2017 Vistogard® and Voraxaze® Added to Revised Guidelines for Stocking of Antidotes in US Hospitals
13 June 2017 New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation
07 March 2017 SnakeBite911™ Expands Free Snake Education and Snakebite Safety App to Android Devices
17 August 2016 CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016
09 March 2016 New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation
11 December 2015 BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine
10 September 2015 BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU)
10 October 2014 BTG reaches settlement regarding CroFab® patent litigation
08 January 2014 BTG’s manufacturing facility in west Wales awarded top Environmental Standard
12 April 2013 BTG plc: Varisolve® NDA accepted for full review by FDA
04 February 2013 BTG plc: Varisolve® NDA submitted to the FDA
05 September 2012 CMS grants new prospective reimbursement for Voraxaze®
04 June 2012 BTG announces data presentation on Voraxaze® (glucarpidase) at the American Society of Clinical Oncology Annual Meeting
30 April 2012 Voraxaze® (glucarpidase) Launched in the US
23 April 2012 BTG Announces Positive Results from Second US Pivotal Phase III Trial of Varisolve®
28 March 2012 DigiFab® 40 mg/vial digoxin immune Fab
30 January 2012 BTG Announces Positive Data from First US Phase III Trial of Varisolve®
18 January 2012 BTG plc: Voraxaze® (glucarpidase) receives US regulatory approval
07 December 2011 BTG plc: Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
20 September 2011 BTG plc: FDA accepts Biologics License Application file for Voraxaze® (glucarpidase) and grants Priority Review
06 July 2011 BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure
25 October 2010 BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab™) as a treatment for severe sepsis
16 September 2010 BTG plc: First Varisolve® US Phase III Trial Initiated
04 February 2010 BTG Receives First European Regulatory Approval for DigiFab™
28 August 2009 BTG Sells HySolv™ Technology to Major Pharmaceutical Company
29 July 2009 BTG plc: AstraZeneca to Progress CytoFab™ into Phase IIb Study

SUPPORTING PHYSICIANS

Our pharmaceutical products are sold throughout the US by a dedicated field force and are made available outside of the US through partners where approved or where permitted on a named patient basis.